PACS Group, Inc. (NYSE: PACS) Stock Competitors & Peer Comparison
See PACS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PACS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PACS | $44.49 | +1.87% | 7.1B | 23.59 | $1.89 | N/A |
| HCA | $419.53 | +4.36% | 91.3B | 14.57 | $28.96 | +0.71% |
| THC | $264.38 | +2.05% | 21.7B | 15.61 | $17.24 | N/A |
| EHC | $120.71 | +0.20% | 12.1B | 20.82 | $5.84 | +0.63% |
| FMS | $22.33 | -0.53% | 12B | 8.39 | $2.66 | +3.87% |
| DVA | $182.00 | +1.08% | 11.7B | 14.30 | $12.80 | N/A |
| UHS | $171.97 | +0.04% | 10.6B | 7.80 | $22.54 | +0.45% |
| ENSG | $172.05 | +0.88% | 10B | 24.89 | $6.90 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| CHE | $510.02 | -1.73% | 6.8B | 24.00 | $21.61 | +0.49% |
Stock Comparison
HCA Healthcare, Inc. (NYSE: HCA)
PACS vs HCA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, HCA has a market cap of 91.3B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while HCA trades at $419.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas HCA's P/E ratio is 14.57. In terms of profitability, PACS's ROE is +0.27%, compared to HCA's ROE of -1.13%. Regarding short-term risk, PACS is less volatile compared to HCA. This indicates lower risk in terms of short-term price fluctuations for PACS.Check HCA's competition here
Tenet Healthcare Corporation (NYSE: THC)
PACS vs THC Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, THC has a market cap of 21.7B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while THC trades at $264.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas THC's P/E ratio is 15.61. In terms of profitability, PACS's ROE is +0.27%, compared to THC's ROE of +0.51%. Regarding short-term risk, PACS is less volatile compared to THC. This indicates lower risk in terms of short-term price fluctuations for PACS.Check THC's competition here
Encompass Health Corporation (NYSE: EHC)
PACS vs EHC Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, EHC has a market cap of 12.1B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while EHC trades at $120.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas EHC's P/E ratio is 20.82. In terms of profitability, PACS's ROE is +0.27%, compared to EHC's ROE of +0.25%. Regarding short-term risk, PACS is less volatile compared to EHC. This indicates lower risk in terms of short-term price fluctuations for PACS.Check EHC's competition here
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)
PACS vs FMS Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, FMS has a market cap of 12B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while FMS trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas FMS's P/E ratio is 8.39. In terms of profitability, PACS's ROE is +0.27%, compared to FMS's ROE of +0.07%. Regarding short-term risk, PACS is more volatile compared to FMS. This indicates higher risk in terms of short-term price fluctuations for PACS.Check FMS's competition here
DaVita Inc. (NYSE: DVA)
PACS vs DVA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, DVA has a market cap of 11.7B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while DVA trades at $182.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas DVA's P/E ratio is 14.30. In terms of profitability, PACS's ROE is +0.27%, compared to DVA's ROE of -1.24%. Regarding short-term risk, PACS is more volatile compared to DVA. This indicates higher risk in terms of short-term price fluctuations for PACS.Check DVA's competition here
Universal Health Services, Inc. (NYSE: UHS)
PACS vs UHS Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, UHS has a market cap of 10.6B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while UHS trades at $171.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas UHS's P/E ratio is 7.80. In terms of profitability, PACS's ROE is +0.27%, compared to UHS's ROE of +0.21%. Regarding short-term risk, PACS is less volatile compared to UHS. This indicates lower risk in terms of short-term price fluctuations for PACS.Check UHS's competition here
The Ensign Group, Inc. (NASDAQ: ENSG)
PACS vs ENSG Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, ENSG has a market cap of 10B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while ENSG trades at $172.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas ENSG's P/E ratio is 24.89. In terms of profitability, PACS's ROE is +0.27%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, PACS is more volatile compared to ENSG. This indicates higher risk in terms of short-term price fluctuations for PACS.Check ENSG's competition here
Oak Street Health, Inc. (NYSE: OSH)
PACS vs OSH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas OSH's P/E ratio is -17.65. In terms of profitability, PACS's ROE is +0.27%, compared to OSH's ROE of +4.64%. Regarding short-term risk, PACS is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for PACS.Check OSH's competition here
Chemed Corporation (NYSE: CHE)
PACS vs CHE Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CHE trades at $510.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CHE's P/E ratio is 24.00. In terms of profitability, PACS's ROE is +0.27%, compared to CHE's ROE of +0.29%. Regarding short-term risk, PACS is less volatile compared to CHE. This indicates lower risk in terms of short-term price fluctuations for PACS.Check CHE's competition here
Hims & Hers Health, Inc. (NYSE: HIMS)
PACS vs HIMS Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, HIMS has a market cap of 6.2B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while HIMS trades at $27.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas HIMS's P/E ratio is -43.62. In terms of profitability, PACS's ROE is +0.27%, compared to HIMS's ROE of -0.30%. Regarding short-term risk, PACS is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for PACS.Check HIMS's competition here
LHC Group, Inc. (NASDAQ: LHCG)
PACS vs LHCG Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas LHCG's P/E ratio is 82.83. In terms of profitability, PACS's ROE is +0.27%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, PACS is more volatile compared to LHCG. This indicates higher risk in terms of short-term price fluctuations for PACS.Check LHCG's competition here
LifeStance Health Group, Inc. (NASDAQ: LFST)
PACS vs LFST Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, LFST has a market cap of 4.9B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while LFST trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas LFST's P/E ratio is 95.05. In terms of profitability, PACS's ROE is +0.27%, compared to LFST's ROE of +0.03%. Regarding short-term risk, PACS is less volatile compared to LFST. This indicates lower risk in terms of short-term price fluctuations for PACS.Check LFST's competition here
Concentra Group Holdings Parent, Inc. (NYSE: CON)
PACS vs CON Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CON has a market cap of 4.4B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CON trades at $34.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CON's P/E ratio is 21.50. In terms of profitability, PACS's ROE is +0.27%, compared to CON's ROE of +0.47%. Regarding short-term risk, PACS is more volatile compared to CON. This indicates higher risk in terms of short-term price fluctuations for PACS.Check CON's competition here
National HealthCare Corporation (AMEX: NHC)
PACS vs NHC Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, NHC has a market cap of 3.6B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while NHC trades at $224.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas NHC's P/E ratio is 29.09. In terms of profitability, PACS's ROE is +0.27%, compared to NHC's ROE of +0.13%. Regarding short-term risk, PACS is less volatile compared to NHC. This indicates lower risk in terms of short-term price fluctuations for PACS.Check NHC's competition here
Option Care Health, Inc. (NASDAQ: OPCH)
PACS vs OPCH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, OPCH has a market cap of 3.5B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while OPCH trades at $23.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas OPCH's P/E ratio is 13.74. In terms of profitability, PACS's ROE is +0.27%, compared to OPCH's ROE of +0.16%. Regarding short-term risk, PACS is more volatile compared to OPCH. This indicates higher risk in terms of short-term price fluctuations for PACS.Check OPCH's competition here
Amedisys, Inc. (NASDAQ: AMED)
PACS vs AMED Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AMED's P/E ratio is 39.30. In terms of profitability, PACS's ROE is +0.27%, compared to AMED's ROE of +0.11%. Regarding short-term risk, PACS is more volatile compared to AMED. This indicates higher risk in terms of short-term price fluctuations for PACS.Check AMED's competition here
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH)
PACS vs AVAH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AVAH has a market cap of 3.1B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AVAH trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AVAH's P/E ratio is 20.62. In terms of profitability, PACS's ROE is +0.27%, compared to AVAH's ROE of +1.50%. Regarding short-term risk, PACS is more volatile compared to AVAH. This indicates higher risk in terms of short-term price fluctuations for PACS.Check AVAH's competition here
Brookdale Senior Living Inc. (NYSE: BKD)
PACS vs BKD Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while BKD trades at $12.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas BKD's P/E ratio is -20.94. In terms of profitability, PACS's ROE is +0.27%, compared to BKD's ROE of +4.06%. Regarding short-term risk, PACS is less volatile compared to BKD. This indicates lower risk in terms of short-term price fluctuations for PACS.Check BKD's competition here
Guardian Pharmacy Services, Inc. (NYSE: GRDN)
PACS vs GRDN Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, GRDN has a market cap of 2.7B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while GRDN trades at $42.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas GRDN's P/E ratio is 38.03. In terms of profitability, PACS's ROE is +0.27%, compared to GRDN's ROE of +0.31%. Regarding short-term risk, PACS is more volatile compared to GRDN. This indicates higher risk in terms of short-term price fluctuations for PACS.Check GRDN's competition here
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
PACS vs ACHC Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, ACHC has a market cap of 2.6B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while ACHC trades at $28.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas ACHC's P/E ratio is 14.17. In terms of profitability, PACS's ROE is +0.27%, compared to ACHC's ROE of -0.50%. Regarding short-term risk, PACS is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for PACS.Check ACHC's competition here
Addus HomeCare Corporation (NASDAQ: ADUS)
PACS vs ADUS Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, ADUS has a market cap of 2.2B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while ADUS trades at $117.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas ADUS's P/E ratio is 17.85. In terms of profitability, PACS's ROE is +0.27%, compared to ADUS's ROE of +0.10%. Regarding short-term risk, PACS is less volatile compared to ADUS. This indicates lower risk in terms of short-term price fluctuations for PACS.Check ADUS's competition here
Pediatrix Medical Group, Inc. (NYSE: MD)
PACS vs MD Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while MD trades at $27.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas MD's P/E ratio is 12.09. In terms of profitability, PACS's ROE is +0.27%, compared to MD's ROE of +0.20%. Regarding short-term risk, PACS is more volatile compared to MD. This indicates higher risk in terms of short-term price fluctuations for PACS.Check MD's competition here
Select Medical Holdings Corporation (NYSE: SEM)
PACS vs SEM Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas SEM's P/E ratio is 15.43. In terms of profitability, PACS's ROE is +0.27%, compared to SEM's ROE of +0.08%. Regarding short-term risk, PACS is more volatile compared to SEM. This indicates higher risk in terms of short-term price fluctuations for PACS.Check SEM's competition here
Astrana Health, Inc. (NASDAQ: ASTH)
PACS vs ASTH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while ASTH trades at $38.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas ASTH's P/E ratio is 45.86. In terms of profitability, PACS's ROE is +0.27%, compared to ASTH's ROE of +0.05%. Regarding short-term risk, PACS is less volatile compared to ASTH. This indicates lower risk in terms of short-term price fluctuations for PACS.Check ASTH's competition here
Sonida Senior Living, Inc. (NYSE: SNDA)
PACS vs SNDA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, SNDA has a market cap of 1.9B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while SNDA trades at $39.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas SNDA's P/E ratio is -6.39. In terms of profitability, PACS's ROE is +0.27%, compared to SNDA's ROE of -0.26%. Regarding short-term risk, PACS is less volatile compared to SNDA. This indicates lower risk in terms of short-term price fluctuations for PACS.Check SNDA's competition here
Surgery Partners, Inc. (NASDAQ: SGRY)
PACS vs SGRY Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while SGRY trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas SGRY's P/E ratio is 36.21. In terms of profitability, PACS's ROE is +0.27%, compared to SGRY's ROE of -0.05%. Regarding short-term risk, PACS is less volatile compared to SGRY. This indicates lower risk in terms of short-term price fluctuations for PACS.Check SGRY's competition here
Apollo Medical Holdings, Inc. (NASDAQ: AMEH)
PACS vs AMEH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AMEH's P/E ratio is 39.25. In terms of profitability, PACS's ROE is +0.27%, compared to AMEH's ROE of +0.05%. Regarding short-term risk, PACS is less volatile compared to AMEH. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AMEH's competition here
Ardent Health Inc. (NYSE: ARDT)
PACS vs ARDT Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, ARDT has a market cap of 1.6B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while ARDT trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas ARDT's P/E ratio is 8.98. In terms of profitability, PACS's ROE is +0.27%, compared to ARDT's ROE of +0.05%. Regarding short-term risk, PACS is less volatile compared to ARDT. This indicates lower risk in terms of short-term price fluctuations for PACS.Check ARDT's competition here
Agilon Health, Inc. (NYSE: AGL)
PACS vs AGL Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AGL trades at $94.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AGL's P/E ratio is -6.09. In terms of profitability, PACS's ROE is +0.27%, compared to AGL's ROE of -1.19%. Regarding short-term risk, PACS is less volatile compared to AGL. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AGL's competition here
Healthcare Services Group, Inc. (NASDAQ: HCSG)
PACS vs HCSG Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while HCSG trades at $21.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas HCSG's P/E ratio is 17.62. In terms of profitability, PACS's ROE is +0.27%, compared to HCSG's ROE of +0.24%. Regarding short-term risk, PACS is more volatile compared to HCSG. This indicates higher risk in terms of short-term price fluctuations for PACS.Check HCSG's competition here
Innovage Holding Corp. (NASDAQ: INNV)
PACS vs INNV Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, INNV has a market cap of 1.5B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while INNV trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas INNV's P/E ratio is -122.56. In terms of profitability, PACS's ROE is +0.27%, compared to INNV's ROE of -0.01%. Regarding short-term risk, PACS is less volatile compared to INNV. This indicates lower risk in terms of short-term price fluctuations for PACS.Check INNV's competition here
The Pennant Group, Inc. (NASDAQ: PNTG)
PACS vs PNTG Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, PNTG has a market cap of 1.4B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while PNTG trades at $39.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas PNTG's P/E ratio is 30.00. In terms of profitability, PACS's ROE is +0.27%, compared to PNTG's ROE of +0.10%. Regarding short-term risk, PACS is less volatile compared to PNTG. This indicates lower risk in terms of short-term price fluctuations for PACS.Check PNTG's competition here
Nutex Health, Inc. (NASDAQ: NUTX)
PACS vs NUTX Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, NUTX has a market cap of 1.4B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while NUTX trades at $196.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas NUTX's P/E ratio is 7.82. In terms of profitability, PACS's ROE is +0.27%, compared to NUTX's ROE of +0.52%. Regarding short-term risk, PACS is less volatile compared to NUTX. This indicates lower risk in terms of short-term price fluctuations for PACS.Check NUTX's competition here
AMN Healthcare Services, Inc. (NYSE: AMN)
PACS vs AMN Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AMN trades at $33.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AMN's P/E ratio is 11.41. In terms of profitability, PACS's ROE is +0.27%, compared to AMN's ROE of +0.15%. Regarding short-term risk, PACS is less volatile compared to AMN. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AMN's competition here
Brookdale Senior Living Inc. 7. (NYSE: BKDT)
PACS vs BKDT Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas BKDT's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to BKDT's ROE of +4.06%. Regarding short-term risk, PACS is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for PACS.Check BKDT's competition here
U.S. Physical Therapy, Inc. (NYSE: USPH)
PACS vs USPH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while USPH trades at $77.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas USPH's P/E ratio is 30.60. In terms of profitability, PACS's ROE is +0.27%, compared to USPH's ROE of -0.01%. Regarding short-term risk, PACS is more volatile compared to USPH. This indicates higher risk in terms of short-term price fluctuations for PACS.Check USPH's competition here
Talkspace, Inc. (NASDAQ: TALK)
PACS vs TALK Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, TALK has a market cap of 879.4M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while TALK trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas TALK's P/E ratio is 774.34. In terms of profitability, PACS's ROE is +0.27%, compared to TALK's ROE of +0.00%. Regarding short-term risk, PACS is more volatile compared to TALK. This indicates higher risk in terms of short-term price fluctuations for PACS.Check TALK's competition here
GMR Solutions Inc. (NYSE: GMRS)
PACS vs GMRS Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, GMRS has a market cap of 707.8M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while GMRS trades at $12.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas GMRS's P/E ratio is 5.82. In terms of profitability, PACS's ROE is +0.27%, compared to GMRS's ROE of +0.16%. Regarding short-term risk, PACS is less volatile compared to GMRS. This indicates lower risk in terms of short-term price fluctuations for PACS.Check GMRS's competition here
Enhabit, Inc. (NYSE: EHAB)
PACS vs EHAB Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas EHAB's P/E ratio is -197.14. In terms of profitability, PACS's ROE is +0.27%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, PACS is more volatile compared to EHAB. This indicates higher risk in terms of short-term price fluctuations for PACS.Check EHAB's competition here
Starling Oncology, Inc. (NASDAQ: STLN)
PACS vs STLN Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, STLN has a market cap of 628.9M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while STLN trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas STLN's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to STLN's ROE of +2.10%. Regarding short-term risk, PACS is less volatile compared to STLN. This indicates lower risk in terms of short-term price fluctuations for PACS.Check STLN's competition here
The Oncology Institute, Inc. (NASDAQ: TOI)
PACS vs TOI Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, TOI has a market cap of 512.9M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while TOI trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas TOI's P/E ratio is -14.25. In terms of profitability, PACS's ROE is +0.27%, compared to TOI's ROE of +2.10%. Regarding short-term risk, PACS is less volatile compared to TOI. This indicates lower risk in terms of short-term price fluctuations for PACS.Check TOI's competition here
Strata Critical Medical, Inc. (NASDAQ: SRTA)
PACS vs SRTA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, SRTA has a market cap of 451.7M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while SRTA trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas SRTA's P/E ratio is -24.61. In terms of profitability, PACS's ROE is +0.27%, compared to SRTA's ROE of +0.14%. Regarding short-term risk, PACS is less volatile compared to SRTA. This indicates lower risk in terms of short-term price fluctuations for PACS.Check SRTA's competition here
Charming Medical Limited Class A Ordinary Shares (NASDAQ: MCTA)
PACS vs MCTA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas MCTA's P/E ratio is 419.36. In terms of profitability, PACS's ROE is +0.27%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, PACS is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for PACS.Check MCTA's competition here
Community Health Systems, Inc. (NYSE: CYH)
PACS vs CYH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CYH has a market cap of 414.6M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CYH trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CYH's P/E ratio is 4.03. In terms of profitability, PACS's ROE is +0.27%, compared to CYH's ROE of +0.21%. Regarding short-term risk, PACS is less volatile compared to CYH. This indicates lower risk in terms of short-term price fluctuations for PACS.Check CYH's competition here
Auna S.A. (NYSE: AUNA)
PACS vs AUNA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AUNA has a market cap of 384.2M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AUNA trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AUNA's P/E ratio is 4.68. In terms of profitability, PACS's ROE is +0.27%, compared to AUNA's ROE of +0.01%. Regarding short-term risk, PACS is more volatile compared to AUNA. This indicates higher risk in terms of short-term price fluctuations for PACS.Check AUNA's competition here
Viemed Healthcare, Inc. (NASDAQ: VMD)
PACS vs VMD Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, VMD has a market cap of 333.7M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while VMD trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas VMD's P/E ratio is 24.33. In terms of profitability, PACS's ROE is +0.27%, compared to VMD's ROE of +0.10%. Regarding short-term risk, PACS is more volatile compared to VMD. This indicates higher risk in terms of short-term price fluctuations for PACS.Check VMD's competition here
Capital Senior Living Corporation (NYSE: CSU)
PACS vs CSU Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CSU's P/E ratio is 0.67. In terms of profitability, PACS's ROE is +0.27%, compared to CSU's ROE of -0.33%. Regarding short-term risk, PACS is less volatile compared to CSU. This indicates lower risk in terms of short-term price fluctuations for PACS.Check CSU's competition here
AirSculpt Technologies, Inc. (NASDAQ: AIRS)
PACS vs AIRS Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AIRS has a market cap of 184.1M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AIRS trades at $2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AIRS's P/E ratio is -87.00. In terms of profitability, PACS's ROE is +0.27%, compared to AIRS's ROE of -0.13%. Regarding short-term risk, PACS is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AIRS's competition here
The Joint Corp. (NASDAQ: JYNT)
PACS vs JYNT Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, JYNT has a market cap of 115.3M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while JYNT trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas JYNT's P/E ratio is 80.90. In terms of profitability, PACS's ROE is +0.27%, compared to JYNT's ROE of +0.22%. Regarding short-term risk, PACS is less volatile compared to JYNT. This indicates lower risk in terms of short-term price fluctuations for PACS.Check JYNT's competition here
Five Star Senior Living Inc. (NASDAQ: FVE)
PACS vs FVE Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas FVE's P/E ratio is -5.64. In terms of profitability, PACS's ROE is +0.27%, compared to FVE's ROE of -0.15%. Regarding short-term risk, PACS is more volatile compared to FVE. This indicates higher risk in terms of short-term price fluctuations for PACS.Check FVE's competition here
Kindly MD, Inc. (NASDAQ: KDLYW)
PACS vs KDLYW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas KDLYW's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to KDLYW's ROE of -1.05%. Regarding short-term risk, PACS is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for PACS.Check KDLYW's competition here
Park Dental Partners, Inc. Common Stock (NASDAQ: PARK)
PACS vs PARK Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, PARK has a market cap of 94.7M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while PARK trades at $20.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas PARK's P/E ratio is 28.35. In terms of profitability, PACS's ROE is +0.27%, compared to PARK's ROE of -0.18%. Regarding short-term risk, PACS is less volatile compared to PARK. This indicates lower risk in terms of short-term price fluctuations for PACS.Check PARK's competition here
biote Corp. (NASDAQ: BTMD)
PACS vs BTMD Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, BTMD has a market cap of 64M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while BTMD trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas BTMD's P/E ratio is 13.18. In terms of profitability, PACS's ROE is +0.27%, compared to BTMD's ROE of -0.09%. Regarding short-term risk, PACS is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for PACS.Check BTMD's competition here
AlerisLife Inc. (NASDAQ: ALR)
PACS vs ALR Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas ALR's P/E ratio is -1.11. In terms of profitability, PACS's ROE is +0.27%, compared to ALR's ROE of -0.15%. Regarding short-term risk, PACS is more volatile compared to ALR. This indicates higher risk in terms of short-term price fluctuations for PACS.Check ALR's competition here
DocGo Inc. (NASDAQ: DCGO)
PACS vs DCGO Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, DCGO has a market cap of 36.5M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while DCGO trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas DCGO's P/E ratio is -0.20. In terms of profitability, PACS's ROE is +0.27%, compared to DCGO's ROE of -1.16%. Regarding short-term risk, PACS is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for PACS.Check DCGO's competition here
Cryo-Cell International, Inc. (AMEX: CCEL)
PACS vs CCEL Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CCEL has a market cap of 33.1M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CCEL trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CCEL's P/E ratio is -13.70. In terms of profitability, PACS's ROE is +0.27%, compared to CCEL's ROE of +0.14%. Regarding short-term risk, PACS is more volatile compared to CCEL. This indicates higher risk in terms of short-term price fluctuations for PACS.Check CCEL's competition here
IMAC Holdings, Inc. (NASDAQ: IMAC)
PACS vs IMAC Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas IMAC's P/E ratio is -2.27. In terms of profitability, PACS's ROE is +0.27%, compared to IMAC's ROE of +0.00%. Regarding short-term risk, PACS is less volatile compared to IMAC. This indicates lower risk in terms of short-term price fluctuations for PACS.Check IMAC's competition here
P3 Health Partners Inc. (NASDAQ: PIII)
PACS vs PIII Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, PIII has a market cap of 28.2M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while PIII trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas PIII's P/E ratio is -0.26. In terms of profitability, PACS's ROE is +0.27%, compared to PIII's ROE of +1.61%. Regarding short-term risk, PACS is less volatile compared to PIII. This indicates lower risk in terms of short-term price fluctuations for PACS.Check PIII's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
PACS vs EUDA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, EUDA has a market cap of 24.5M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while EUDA trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas EUDA's P/E ratio is -24.74. In terms of profitability, PACS's ROE is +0.27%, compared to EUDA's ROE of +1.20%. Regarding short-term risk, PACS is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for PACS.Check EUDA's competition here
Cano Health, Inc. (NYSE: CANO-WT)
PACS vs CANO-WT Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, PACS is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for PACS.Check CANO-WT's competition here
Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH)
PACS vs AIH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AIH's P/E ratio is -2.78. In terms of profitability, PACS's ROE is +0.27%, compared to AIH's ROE of +1.16%. Regarding short-term risk, PACS is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AIH's competition here
P3 Health Partners Inc. (NASDAQ: PIIIW)
PACS vs PIIIW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, PIIIW has a market cap of 14.9M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas PIIIW's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to PIIIW's ROE of +1.61%. Regarding short-term risk, PACS is less volatile compared to PIIIW. This indicates lower risk in terms of short-term price fluctuations for PACS.Check PIIIW's competition here
Cano Health, Inc. (NYSE: CANO)
PACS vs CANO Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CANO's P/E ratio is -0.01. In terms of profitability, PACS's ROE is +0.27%, compared to CANO's ROE of -1.49%. Regarding short-term risk, PACS is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for PACS.Check CANO's competition here
Avem Health Partners, Inc. (NYSE: FPCG)
PACS vs FPCG Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas FPCG's P/E ratio is 0.09. In terms of profitability, PACS's ROE is +0.27%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, PACS is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for PACS.Check FPCG's competition here
American Shared Hospital Services (AMEX: AMS)
PACS vs AMS Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AMS has a market cap of 9.9M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AMS trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AMS's P/E ratio is -5.90. In terms of profitability, PACS's ROE is +0.27%, compared to AMS's ROE of -0.07%. Regarding short-term risk, PACS is less volatile compared to AMS. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AMS's competition here
Field Trip Health Ltd. (NASDAQ: FTRP)
PACS vs FTRP Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas FTRP's P/E ratio is -1.22. In terms of profitability, PACS's ROE is +0.27%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, PACS is less volatile compared to FTRP. This indicates lower risk in terms of short-term price fluctuations for PACS.Check FTRP's competition here
Basel Medical Group Ltd Ordinary Shares (NASDAQ: BMGL)
PACS vs BMGL Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, BMGL has a market cap of 7.3M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while BMGL trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas BMGL's P/E ratio is -0.88. In terms of profitability, PACS's ROE is +0.27%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, PACS is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for PACS.Check BMGL's competition here
20/20 Biolabs Inc. (NASDAQ: AIDX)
PACS vs AIDX Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AIDX has a market cap of 6.9M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AIDX trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AIDX's P/E ratio is -1.06. In terms of profitability, PACS's ROE is +0.27%, compared to AIDX's ROE of -3.87%. Regarding short-term risk, PACS is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AIDX's competition here
ModivCare Inc. (NASDAQ: MODV)
PACS vs MODV Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas MODV's P/E ratio is -0.03. In terms of profitability, PACS's ROE is +0.27%, compared to MODV's ROE of +1.36%. Regarding short-term risk, PACS is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for PACS.Check MODV's competition here
Greenbrook TMS Inc. (NASDAQ: GBNH)
PACS vs GBNH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas GBNH's P/E ratio is -0.06. In terms of profitability, PACS's ROE is +0.27%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, PACS is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for PACS.Check GBNH's competition here
Regional Health Properties, Inc. (AMEX: RHE)
PACS vs RHE Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas RHE's P/E ratio is -1.79. In terms of profitability, PACS's ROE is +0.27%, compared to RHE's ROE of -1.31%. Regarding short-term risk, PACS is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for PACS.Check RHE's competition here
Regional Health Properties, Inc. (AMEX: RHE-PA)
PACS vs RHE-PA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, PACS's ROE is +0.27%, compared to RHE-PA's ROE of +1.09%. Regarding short-term risk, PACS is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for PACS.Check RHE-PA's competition here
The Oncology Institute, Inc. (NASDAQ: TOIIW)
PACS vs TOIIW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, TOIIW has a market cap of 4.7M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas TOIIW's P/E ratio is -0.17. In terms of profitability, PACS's ROE is +0.27%, compared to TOIIW's ROE of +2.10%. Regarding short-term risk, PACS is more volatile compared to TOIIW. This indicates higher risk in terms of short-term price fluctuations for PACS.Check TOIIW's competition here
Starling Oncology Inc. Wt (NASDAQ: STLNW)
PACS vs STLNW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, STLNW has a market cap of 4M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while STLNW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas STLNW's P/E ratio is -0.13. In terms of profitability, PACS's ROE is +0.27%, compared to STLNW's ROE of +2.10%. Regarding short-term risk, PACS is less volatile compared to STLNW. This indicates lower risk in terms of short-term price fluctuations for PACS.Check STLNW's competition here
IMAC Holdings, Inc. (NASDAQ: IMACW)
PACS vs IMACW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas IMACW's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, PACS is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for PACS.Check IMACW's competition here
Endovia Health Sciences, Inc. (AMEX: EDVA)
PACS vs EDVA Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, EDVA has a market cap of 1.6M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while EDVA trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas EDVA's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to EDVA's ROE of N/A. Regarding short-term risk, PACS is less volatile compared to EDVA. This indicates lower risk in terms of short-term price fluctuations for PACS.Check EDVA's competition here
EUDA Health Holdings Limited (NASDAQ: EUDAW)
PACS vs EUDAW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, EUDAW has a market cap of 1.1M. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while EUDAW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas EUDAW's P/E ratio is 0.04. In terms of profitability, PACS's ROE is +0.27%, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, PACS is more volatile compared to EUDAW. This indicates higher risk in terms of short-term price fluctuations for PACS.Check EUDAW's competition here
Concord Medical Services Holdings Limited (NYSE: CCM)
PACS vs CCM Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, CCM has a market cap of 605.8K. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while CCM trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas CCM's P/E ratio is -0.28. In terms of profitability, PACS's ROE is +0.27%, compared to CCM's ROE of +0.06%. Regarding short-term risk, PACS is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for PACS.Check CCM's competition here
NewGenIvf Group Limited (NASDAQ: NIVF)
PACS vs NIVF Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, NIVF has a market cap of 72K. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while NIVF trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas NIVF's P/E ratio is 0.56. In terms of profitability, PACS's ROE is +0.27%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, PACS is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for PACS.Check NIVF's competition here
NewGenIvf Group Limited (NASDAQ: NIVFW)
PACS vs NIVFW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, NIVFW has a market cap of 43.2K. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, PACS's ROE is +0.27%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, PACS is more volatile compared to NIVFW. This indicates higher risk in terms of short-term price fluctuations for PACS.Check NIVFW's competition here
Mobile-health Network Solutions Class A Ordinary Shares (NASDAQ: MNDR)
PACS vs MNDR Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, MNDR has a market cap of 36.9K. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while MNDR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas MNDR's P/E ratio is -0.04. In terms of profitability, PACS's ROE is +0.27%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, PACS is less volatile compared to MNDR. This indicates lower risk in terms of short-term price fluctuations for PACS.Check MNDR's competition here
Talkspace, Inc. (NASDAQ: TALKW)
PACS vs TALKW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, TALKW has a market cap of 33.5K. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas TALKW's P/E ratio is 0.00. In terms of profitability, PACS's ROE is +0.27%, compared to TALKW's ROE of +0.00%. Regarding short-term risk, PACS is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for PACS.Check TALKW's competition here
Skylight Health Group Inc. (NASDAQ: SLHGP)
PACS vs SLHGP Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, PACS's ROE is +0.27%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, PACS is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for PACS.Check SLHGP's competition here
Hanger, Inc. (NYSE: HNGR)
PACS vs HNGR Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas HNGR's P/E ratio is 19.71. In terms of profitability, PACS's ROE is +0.27%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, PACS is more volatile compared to HNGR. This indicates higher risk in terms of short-term price fluctuations for PACS.Check HNGR's competition here
Almost Family Inc. (NASDAQ: AFAM)
PACS vs AFAM Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas AFAM's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, PACS is less volatile compared to AFAM. This indicates lower risk in terms of short-term price fluctuations for PACS.Check AFAM's competition here
SOC Telemed, Inc. (NASDAQ: TLMD)
PACS vs TLMD Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas TLMD's P/E ratio is -1.60. In terms of profitability, PACS's ROE is +0.27%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, PACS is more volatile compared to TLMD. This indicates higher risk in terms of short-term price fluctuations for PACS.Check TLMD's competition here
New Frontier Health Corporation (NYSE: NFH)
PACS vs NFH Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, NFH has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas NFH's P/E ratio is -19.75. In terms of profitability, PACS's ROE is +0.27%, compared to NFH's ROE of -0.06%. Regarding short-term risk, PACS is more volatile compared to NFH. This indicates higher risk in terms of short-term price fluctuations for PACS.Check NFH's competition here
Kindred Healthcare, Inc. (NYSE: KND)
PACS vs KND Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, KND has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas KND's P/E ratio is -1.14. In terms of profitability, PACS's ROE is +0.27%, compared to KND's ROE of -0.53%. Regarding short-term risk, PACS is more volatile compared to KND. This indicates higher risk in terms of short-term price fluctuations for PACS.Check KND's competition here
Diversicare Healthcare Services, Inc. (NASDAQ: DVCR)
PACS vs DVCR Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas DVCR's P/E ratio is 28.34. In terms of profitability, PACS's ROE is +0.27%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, PACS is more volatile compared to DVCR. This indicates higher risk in terms of short-term price fluctuations for PACS.Check DVCR's competition here
SOC Telemed, Inc. (NASDAQ: TLMDW)
PACS vs TLMDW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas TLMDW's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, PACS is less volatile compared to TLMDW. This indicates lower risk in terms of short-term price fluctuations for PACS.Check TLMDW's competition here
ATI Physical Therapy, Inc. (NYSE: ATIP-WT)
PACS vs ATIP-WT Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, PACS is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for PACS.Check ATIP-WT's competition here
Tivity Health, Inc. (NASDAQ: TVTY)
PACS vs TVTY Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas TVTY's P/E ratio is 19.06. In terms of profitability, PACS's ROE is +0.27%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, PACS is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for PACS.Check TVTY's competition here
DocGo Inc. (NASDAQ: DCGOW)
PACS vs DCGOW Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas DCGOW's P/E ratio is N/A. In terms of profitability, PACS's ROE is +0.27%, compared to DCGOW's ROE of -1.16%. Regarding short-term risk, PACS is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for PACS.Check DCGOW's competition here
Skylight Health Group Inc. (NASDAQ: SLHG)
PACS vs SLHG Comparison September 2026
PACS Group, Inc. (NYSE: PACS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACS stands at 7.1B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, PACS is priced at $44.49 on the NYSE, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACS currently has a P/E ratio of 23.59, whereas SLHG's P/E ratio is -1.48. In terms of profitability, PACS's ROE is +0.27%, compared to SLHG's ROE of N/A. Regarding short-term risk, PACS is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for PACS.Check SLHG's competition here